HONG KONG, Jan. 29, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results